Akari Therapeutics PLC (AKTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.54M
Last updated: Nov 17, 2026 at 4:10 PM ET
Akari Therapeutics PLC (AKTX) Statistics
Akari Therapeutics (AKTX) has a market cap of $15.54M and an enterprise value of $9.80M. Its share count is up 20251.72% from a year earlier. It holds $5.74M more cash than debt, 36.96% of its market cap.
Total Valuation
Enterprise value is 36.96% below the market cap, as cash exceeds debt.
| Market Cap | $15.54M |
|---|---|
| Enterprise Value | $9.80M |
| Latest price (Nov 17, 2026) | $5.70 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 73.05% over 52 weeks and trades 34.63% below its 50-day average.
| Beta (1Y) | 2.33 |
|---|---|
| 52-Week Change | -73.05% |
| 1-Month Change | -42.37% |
| 3-Month Change | -27.85% |
| 6-Month Change | +52.41% |
| 5-Year Change | -99.38% |
| 10-Year Change | -99.89% |
| Total Return (1Y) | -73.05% |
| Total Return (3Y CAGR) | -64.55% |
| Total Return (5Y CAGR) | -65.90% |
| Return vs SPY (1Y) | -84.70% |
| Max Drawdown (1Y) | -85.58% |
| Max Drawdown (3Y) | -98.22% |
| Sharpe Ratio (1Y) | -0.68 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $8.72 |
| 200-Day Average | $8.88 |
| 52-Week Range | $3.02 to $29.32 |
| RSI (14 Days) | 36.5 |
| Average Volume (20 Days) | 38.62K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.48x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.48x |
|---|---|
| Quick Ratio | 0.48x |
| Debt / Equity | 0.00x |
| Interest Coverage | -32.35x |
Returns and Efficiency
| Return on Assets (ROA) | -84.64% |
|---|---|
| ROIC (5Y Average) | 477.21% |
Scores
AKTX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Balance Sheet
| Cash and Equivalents | $5.74M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.74M |
Balance sheet as of Sep 30, 2026.
Dividends and Yields
AKTX does not pay a dividend. Its free cash flow yield is -67.90%.
| FCF Yield | -67.90% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-40 reverse split on Mar 31, 2026.
| Last Split Date | Mar 31, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:40 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About AKTX
What is AKTX's market cap?
Akari Therapeutics has a market cap of $15.54M. Its enterprise value, which adds debt and subtracts cash, is $9.80M.
How many shares of AKTX are outstanding?
Akari Therapeutics has 3.32M shares outstanding. The count is up 20251.72% from a year earlier.
Does AKTX pay a dividend?
No. Akari Therapeutics does not pay a dividend.
How much debt does AKTX have?
Akari Therapeutics has $0 of total debt and $5.74M of cash and equivalents, a net cash position of $5.74M.
AKTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors